Epidemiology and distribution of 207 rare diseases in China: A systematic literature review.

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL Intractable & rare diseases research Pub Date : 2024-05-31 DOI:10.5582/irdr.2024.01001
Yukun Wang, Yicheng Liu, Guoyao Du, Yonghui Liu, Ying Zeng
{"title":"Epidemiology and distribution of 207 rare diseases in China: A systematic literature review.","authors":"Yukun Wang, Yicheng Liu, Guoyao Du, Yonghui Liu, Ying Zeng","doi":"10.5582/irdr.2024.01001","DOIUrl":null,"url":null,"abstract":"<p><p>Epidemiological data on rare diseases in China are currently limited. The objective of this study was to provide a comprehensive understanding of the prevalence and incidence of rare diseases by systematically analyzing the available epidemiological data. We conducted a comprehensive search of English and Chinese databases, the Incidence and Prevalence Database, the Chinese Rare Disease Guideline, and the Taiwan Health Promotion Administration from 2010 to 2023. We identified the top diseases and regions based on epidemiological data and present the maximum, minimum, and median prevalence and incidence values in tables and forest plots. 1,264 prevalence and incidence data were retrieved from 277 studies, guidelines and official websites, covering 110 rare diseases (53.1%) and 32 regions (94.1%). In terms of geographical regions, incidence or prevalence data were available for 32 regions (94.1%), excluding Tibet Hui Autonomous Region and Macao Special Administrative Region. In terms of rate, 60 and 77 out of 207 diseases (29.0% and 37.2%) had available incidence and prevalence data, respectively. Eight diseases had an incidence rate equal to or greater than that of 1,000 patients per million. The present study provides a comprehensive epidemiological analysis and valuable insights into the prevalence and incidence of rare diseases in China. Our findings underscore the pressing need for sustained drug research and medical support for individuals and families impacted by rare diseases.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145401/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intractable & rare diseases research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/irdr.2024.01001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Epidemiological data on rare diseases in China are currently limited. The objective of this study was to provide a comprehensive understanding of the prevalence and incidence of rare diseases by systematically analyzing the available epidemiological data. We conducted a comprehensive search of English and Chinese databases, the Incidence and Prevalence Database, the Chinese Rare Disease Guideline, and the Taiwan Health Promotion Administration from 2010 to 2023. We identified the top diseases and regions based on epidemiological data and present the maximum, minimum, and median prevalence and incidence values in tables and forest plots. 1,264 prevalence and incidence data were retrieved from 277 studies, guidelines and official websites, covering 110 rare diseases (53.1%) and 32 regions (94.1%). In terms of geographical regions, incidence or prevalence data were available for 32 regions (94.1%), excluding Tibet Hui Autonomous Region and Macao Special Administrative Region. In terms of rate, 60 and 77 out of 207 diseases (29.0% and 37.2%) had available incidence and prevalence data, respectively. Eight diseases had an incidence rate equal to or greater than that of 1,000 patients per million. The present study provides a comprehensive epidemiological analysis and valuable insights into the prevalence and incidence of rare diseases in China. Our findings underscore the pressing need for sustained drug research and medical support for individuals and families impacted by rare diseases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国 207 种罕见病的流行病学和分布情况:系统文献综述。
目前,中国罕见病的流行病学数据十分有限。本研究旨在通过系统分析现有的流行病学数据,全面了解罕见病的流行和发病情况。我们对 2010 年至 2023 年的中英文数据库、发病率和流行率数据库、中国罕见病指南和台湾健康促进署进行了全面检索。我们根据流行病学数据确定了最主要的疾病和地区,并以表格和森林图的形式列出了流行率和发病率的最大值、最小值和中值。我们从 277 项研究、指南和官方网站中检索到 1264 项流行率和发病率数据,涵盖 110 种罕见疾病(53.1%)和 32 个地区(94.1%)。就地区而言,除西藏回族自治区和澳门特别行政区外,32 个地区(94.1%)均有发病率或流行率数据。在发病率方面,207 种疾病中分别有 60 种和 77 种(29.0% 和 37.2%)有发病率和患病率数据。有 8 种疾病的发病率等于或高于每百万人中 1,000 名患者的发病率。本研究对中国罕见病的流行率和发病率进行了全面的流行病学分析,并提供了宝贵的见解。我们的研究结果突出表明,受罕见病影响的个人和家庭迫切需要持续的药物研究和医疗支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Intractable & rare diseases research
Intractable & rare diseases research MEDICINE, GENERAL & INTERNAL-
CiteScore
2.10
自引率
0.00%
发文量
29
期刊最新文献
A patient treated with ofatumumab for myasthenia gravis in conjunction with systemic lupus erythematosus and thyroid carcinoma. Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China. Epidemiological estimates of paroxysmal nocturnal hemoglobinuria in Bulgaria. Functional impairments in NBIA patients: Preliminary results. Genetic analysis of a novel FBN1 mutation in a pediatric Marfan syndrome patient.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1